Venlafaxine hyponatraemia: incidence, mechanism and management

References

• Luzecky MH, Burman KD, Schultz ER. The syndrome of inappropriate secretion of antidiuretic hormone associated with amitriptyline administration. South Med J 1974; 67: 495–497
   PubMed Web of Science ®Google Scholar
• Fabian TJ, Amico JA, Kroboth PD, Mulsant BH, Reynolds CF, Pollock BG. Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Geriatr Psychiatry Neurol 2003; 16: 160–164
   PubMed Web of Science ®Google Scholar
• Oslin DW, Ten Have TR, Streim JE, et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents [see comment]. J Clin Psychiatry 2003; 64: 875–882
   PubMed Web of Science ®Google Scholar
• Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. Arch Intern Med 2004; 164: 327–332
   PubMedGoogle Scholar
• Miller M, Hecker MS, Friedlander DA, Carter JM. Apparent idiopathic hyponatremia in an ambulatory geriatric population. J Am Geriatr Soc 1996; 44: 404–408
   PubMed Web of Science ®Google Scholar
• Miller, MM, Morley, JE, Rubenstein, LZ. Hyponatraemia in a nursing home population. J Am Geriatr Soc 1995; 43:1410–1413.
   PubMed Web of Science ®Google Scholar
• Pillans PI, Coulter DM. Fluoxetine and hyponatraemia: a potential hazard in the elderly. N Z Med J 1994; 107: 85–86
   PubMed Web of Science ®Google Scholar
• Strachan J, Shepherd J. Hyponatraemia associated with the use of selective serotonin re-uptake inhibitors. Aust N Z J Psychiatry 1998; 32: 295–298
   PubMed Web of Science ®Google Scholar
• Bouman WP, Trescoli-Serano C, Johnson H, Jones RG. Transient hyponatraemia and SIADH associated with citalopram. Pharmaceut J 1997; 259: 132
   Google Scholar
• Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R. Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people [see comment]. Br J Clin Pharmacol 1999; 47: 211–217
   PubMed Web of Science ®Google Scholar
• Catalano MC, Catalano G, Kanfer SN, Toner LC, Stock SL, Taylor WD. The effect of sertraline on routine blood chemistry values. Clin Neuropharmacol 2000; 23: 267–270
   PubMed Web of Science ®Google Scholar
• Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002; 17: 231–237
   PubMed Web of Science ®Google Scholar
• Degner D, Grohman R, Kropp S. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37(Suppl 1)S39–S45
   PubMedGoogle Scholar
• Wee R, Lim WK. Selective serotonin re-uptake inhibitors (SSRI's) and hyponatraemia in the elderly. Int J Geriatr Psychiatry 2004; 19: 590–591
   PubMed Web of Science ®Google Scholar
• Movig KL, Leufkens HG, Lenderink AW, Egberts AC. Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly. Eur J Clin Pharmacol 2002; 58: 143–148
   PubMed Web of Science ®Google Scholar
• Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. [erratum appears in Can Med Assoc J 1996 15; 155:1043]. Can Med Assoc J 1996; 155: 519–527
   PubMed Web of Science ®Google Scholar
• Spigset O, Hedenmalm K. Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Pharmacotherapy 1997; 17: 348–352
   PubMed Web of Science ®Google Scholar
• Movig KL, Leufkens HG, Lenderink AW, et al. Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol 2002; 53: 363–369
   PubMed Web of Science ®Google Scholar
• Wijnen HH, van Schendel FM, Olde Rikkert MG, van der Hooft CS, van Puijenbroek EP. [Hyponatraemia during the use of selective serotonin re-uptake inhibitors (SSRIs): reports from 1992–2002]. Ned Tijdschr Geneesk 2004; 148: 1921–1924
   PubMedGoogle Scholar
• Siegler EL, Tamres D, Berlin JA, Allen-Taylor L, Strom BL. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med 1995; 155: 953–957
   PubMed Web of Science ®Google Scholar
• Sharma H, Pompei P. Antidepressant-induced hyponatraemia in the aged. Avoidance and management strategies. Drugs Aging 1996; 8: 430–435
   PubMed Web of Science ®Google Scholar
• Kovacs L, Robertson GL. Syndrome of inappropriate antidiuresis. Endocrinol Metab Clin North Am 1992; 21: 859–875
   PubMed Web of Science ®Google Scholar
• Roxanas MG. Mirtazapine-induced hyponatraemia. Med J Aust 2003; 179: 453–454
   PubMed Web of Science ®Google Scholar
• Sand PG, Atzinger AK, Buwe A. SNRI and hyponatremia [comment]. Int J Geriatr Psychiatry 2002; 17: 491–492
   PubMed Web of Science ®Google Scholar
• Maramattom BV. Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures. Neurology 2006; 66: 773–774
   PubMed Web of Science ®Google Scholar
• Blass DM, Pearson VE. SIADH with multiple antidepressants in a geriatric patient. J Clin Psychiatry 2000; 61: 448–449
   PubMed Web of Science ®Google Scholar
• Alderman CP. Syndrome of inappropriate antidiuretic hormone secretion secondary to venlafaxine. J Pharm Pract Res 2002; 32: 35–36
   Google Scholar
• Critchlow S. Hyponatremia in elderly psychiatric inpatients. Int J Geriatr Psychiatry 1998; 13: 816–818
   PubMed Web of Science ®Google Scholar
• Meynaar IA, Peeters AJ, Mulder AH, Ottervanger JP. Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine. Neth J Med 1997; 50: 243–245
   PubMed Web of Science ®Google Scholar
• Gupta AK, Saravay SM. Venlafaxine-induced hyponatremia. J Clin Psychopharmacol 1997; 17: 223–225
   PubMed Web of Science ®Google Scholar
• Bourgeois JA, Babine SE, Bahadur N. A case of SIADH and hyponatremia associated with citalopram. Psychosomatics 2002; 43: 241–242
   PubMed Web of Science ®Google Scholar
• Masood GR, Karki SD, Patterson WR. Hyponatremia with venlafaxine [see comment]. Ann Pharmacother 1998; 32: 49–51
   PubMed Web of Science ®Google Scholar
• Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock [see comment]. Chest 2001; 120: 989–1002
   PubMed Web of Science ®Google Scholar
• Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280–294
   PubMed Web of Science ®Google Scholar
• Anderson IK, Martin GR, Ramage AG. Central administration of 5-HT activates 5-HT1A receptors to cause sympathoexcitation and 5-HT2/5-HT1C receptors to release vasopressin in anaesthetized rats. Br J Pharmacol 1992; 107: 1020–1028
   PubMed Web of Science ®Google Scholar
• Brownfield MS, Greathouse J, Lorens SA, Armstrong J, Urban JH, Van de Kar LD. Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology 1988; 47: 277–283
   PubMed Web of Science ®Google Scholar
• Leibowitz SF, Eidelman D, Suh JS, Diaz S, Sladek CD. Mapping study of noradrenergic stimulation of vasopressin release. Exp Neurol 1990; 110: 298–305
   PubMed Web of Science ®Google Scholar
• Frolkis VV, Golovchenko SF, Medved VI, Frolkis RA. Vasopressin and cardiovascular system in aging. Gerontology 1982; 28: 290–302
   PubMed Web of Science ®Google Scholar
• Marar IE, Amico JA. Vasopressin, oxytocin, corticotrophin-releasing factor, and sodium responses during fluoxetine administration in the rat. Endocrine 1998; 8: 13–18
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Weber JS, Magiakou MA, Gunn H, Chrousos GP. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion [see comment]. J Clin Endocrinol Metab 1994; 79: 934–939
   PubMed Web of Science ®Google Scholar